New drug combo aims to ease muscle weakness in myasthenia gravis

NCT ID NCT07284420

Recruiting now Disease control Sponsor: argenx Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether adding empasiprubart to the existing drug efgartigimod can improve symptoms and daily function in people with generalized myasthenia gravis who still have symptoms on efgartigimod alone. About 70 participants will receive both drugs intravenously. The main goal is to check safety and whether the combination leads to better symptom control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: empasiprubart and efgartigimod (both given intravenously)
What this could lead to: If successful, this combination could offer better symptom control and quality of life for people with generalized myasthenia gravis who don't respond fully to efgartigimod alone.
What could go wrong: This is an early Phase 2a study with only 70 participants, so results may not apply broadly. Adding a second drug also raises the risk of side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACHR-AB SEROPOSITIVE GENERALIZED MYASTHENIA GRAVIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myasthenia gravis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACHR-AB SEROPOSITIVE GENERALIZED MYASTHENIA GRAVIS GENERALIZED MYASTHENIA GRAVIS GENERALIZED MYASTHENIA GRAVIS (GMG) GMG MG MYASTHENIA GRAVIS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

ASST Papa Giovanni XXIII - Ospedale Papa Giovanni XXIII
RECRUITING

Bergamo, Lombardy, 24127, Italy

Contact Phone: •••-•••-•••• Email: •••••@•••••
Centrum Medyczne Neurologia Slaska
RECRUITING

Katowice, Silesian Voivodeship, 40-689, Poland

Contact Phone: •••-•••-•••• Email: •••••@•••••
Dent Neurologic Institute - Amherst
RECRUITING

Amherst, New York, 14226, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
Duke Early Phase Clinical Research Unit - PPDS
ACTIVE_NOT_RECRUITING

Durham, North Carolina, 27710-0001, United States
Erlanger Health System
RECRUITING

Chattanooga, Tennessee, 37403, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
Henry Ford Health Systems
ACTIVE_NOT_RECRUITING

Detroit, Michigan, 48202-2608, United States
Hospital Regional Universitario de Malaga - Hospital General
RECRUITING

Málaga, Malaga, 29010, Spain

Contact Phone: •••-•••-•••• Email: •••••@•••••
MICS Centrum Medyczne Bydgoszcz
RECRUITING

Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland

Contact Phone: •••-•••-•••• Email: •••••@•••••
National Neuromuscular Research Institute
RECRUITING

Austin, Texas, 78756, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
Ohio State Martha Morehouse Outpatient Care
RECRUITING

Columbus, Ohio, 43221-3502, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
Profound Research LLC - Carlsbad
RECRUITING

Carlsbad, California, 92011, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
UZ Leuven - PPDS
RECRUITING

Leuven, 3000, Belgium

Contact Phone: •••-•••-•••• Email: •••••@•••••
University of South Florida
RECRUITING

Tampa, Florida, 33620, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
University of Texas- San Antonio - Health Science Center - PPDS
RECRUITING

San Antonio, Texas, 78229, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
Visionary Investigators Network
RECRUITING

Miami, Florida, 33176, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.